Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Ovarian Cancer treatment details. Chemotherapy. Immunotherapy. Arizona Cancer Center, Tucson, AZ, United States

Survival: 37.4 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: United States
City/State/Province: Tucson, AZ
Hospital: Arizona Cancer Center
Journal: Link
Date: 5/2008

Patients: This phase 3 trial involved 847 women. The majority (774) had ovarian cancer, and 73 had primary peritoneal cancer. The median age was 56, ranging from 18 to 85 years of age.

Treatment: These women were treated with chemotherapy alone, or chemotherapy and interferon gamma-1b, an immunotherapy. The chemotherapy drugs given were carboplatin and paclitaxel.

Toxicity: Grade 4 neutropenia, leukopenia, thrombocytopenia, and anemia were reported. These were more common in patients treated with the immunotherapy than those given chemotherapy only. The most common toxicities included alopecia, neutropenia, nausea, fatigue, myalgia, constipation, vomiting, and abdominal pain.

Results: The median overall survival was 37.4 months (1138) days for patients being treated with the immunotherapy and chemotherapy. The survival for patients given only chemotherapy was longer than this, but was not calculated yet as the study is still in progress. The immunotherapy treatment was stopped in the group of women receiving it, as it was not providing a benefit, and was associated with more toxicity.

Support: This study was supported by InterMune Inc., which developed interferon gamma-1b as a treatment under the trade name Infergen.

Correspondence: Dr. David S. Alberts

E-mail to a Friend Email Physician More Information